Cytokinetics (CYTK) Director Robert E. Landry Sells 1,000 Shares

What Happened
Robert E. Landry, a director of Cytokinetics, sold 1,000 shares of CYTK in an open-market transaction on September 11, 2026. The shares were disposed at $74.66 each, for a total proceeds of $74,660. This was a sale (not a purchase), which is often routine insider selling rather than a direct bullish signal.

Key Details

• Transaction date: 2026-09-11
• Transaction type/code: Open-market sale (S)
• Price per share: $74.66
• Shares sold: 1,000
• Total value: $74,660
• Shares owned after transaction: Not specified in the provided filing
• Footnotes/plan references: None provided in the supplied details
• Filing timeliness: Report filed on 2026-09-11 (appears timely; no late filing indicated)

Context
Sales by company directors can be routine (portfolio diversification, tax planning, etc.) and do not alone indicate company prospects. Purchases generally carry more informational weight for investors. This filing reports a straightforward open-market sale; no option exercises, gifts, or 10b5‑1 plan details were disclosed in the provided information.